Abstracts tagged "Disease Activity and systemic lupus erythematosus (SLE)"

Abstract Number: 1673 • 2018 ACR/ARHP Annual Meeting
Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population
Cecilia Catoggio¹, Alejandro Martinez Muñoz², María Alejandra Medina³, Rafael Chaparro del Moral⁴, Diana Silvia Klajn⁵, Maximiliano Machado Escobar⁶, Luciana Gonzalez Lucero⁷, Sebastian Muñoz⁸, María Victoria Collado⁹, Graciela N Gómez¹⁰, Judith Sarano¹⁰, Marina Scolnik¹¹, Josefina Marin¹², Julia Romero¹³, Juan Carlos Barreira¹³, María Marta Zalazar¹⁴, Oscar Rillo⁴, Silvia Beatriz Papasidero⁴ and Cecilia N. Pisoni¹⁵, ¹Rheumatology and Immunology, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina, ²Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, San Miguel- Buenos Aires, Argentina, ³Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ⁴Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, CABA, Argentina, ⁵Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁶Rheumatology, Rheumatology Unit, Hospital Padilla, Tucumán, Tucuman, Argentina, ⁷Hospital Angel C. Padilla, Tucuman, Argentina, ⁸Rheumatology Unit, Hospital “Dr. Juan A. Fernández”, CABA, Argentina, ⁹Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁰Rheumatology Unit, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹¹Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ¹²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹³Rheumatology Unit, Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ¹⁴Rheumatology Section, Hospital General de Agudos Dr. Ignacio Pirovano, Buenos Aires, Argentina, ¹⁵Internal Medicine, CEMIC, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina
Background/Purpose: disease activity in Systemic Lupus Erythematosus (SLE) leads to damage, comorbidities and increased overall mortality. Frequent assessment is needed to adapt patients’ management. The…
Abstract Number: 2644 • 2018 ACR/ARHP Annual Meeting
Identifying Response for the Systemic Lupus Erythematosus Disease Activity Glucocorticoid Index (SLEDAI-2KG)
Zahi Touma¹, Dafna D Gladman², Jiandong Su¹, Nicole Anderson³ and Murray Urowitz², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a valid index able to measure disease activity while accounting for glucocorticoid (GC)…
Abstract Number: 1604 • 2017 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman² and Laurence S Magder^3,4, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public Health, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
Abstract Number: 1605 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State Protects Against Most Subtypes of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: In SLE the most common types of organ damage are osteoporotic fractures and cataracts. Other types of organ damage, such as end stage renal…
Abstract Number: 1647 • 2017 ACR/ARHP Annual Meeting
A Lupus Low Disease Activity State Is Associated with Reduced Flare, Lower Organ Damage Accrual, and Better Quality of Life in Patients with Systemic Lupus Erythematosus
Ji-Hyoun Kang¹, Kyung-Eun Lee², Dong-Jin Park¹ and Shin-Seok Lee¹, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), ²Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South)
Background/Purpose: To identify the potential predictors of a lupus low disease activity state (LLDAS), and the relationship between LLDAS and disease flare, organ damage, and…
Abstract Number: 889 • 2017 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)
Eric F Morand¹, Joan T. Merrill², Amy H. Kao³, Cristina Vazquez-Mateo³, Stephen Wax⁴, Peter Chang⁴, Kishore Pudota³ and David A. Isenberg⁵, ¹Monash University, Melbourne, Australia, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Low disease activity (LDA) in lupus patients is increasingly a goal of treatment. For instance, Lupus Low Disease Activity State (LLDAS) attainment is associated…
Abstract Number: 1603 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Can We Relax the Definition and Still Achieve Low Risk of SLE-Related Damage?
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus low disease activity state (LLDAS) is a systemic lupus erythematosus (SLE) outcome measure that combines low disease activity and a 7.5 mg limit…
Abstract Number: 790 • 2016 ACR/ARHP Annual Meeting
Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study
Vera Golder¹, Molla Huq², Kate Franklyn³, Alicia Calderone⁴, Aisha Lateef⁵, Chak Sing Lau⁶, Sandra V. Navarra⁷, Timothy Godfrey^4,8, Shereen Oon⁴, Alberta Y. Hoi³, Eric F Morand³, Mandana Nikpour⁹ and Asia Pacific Lupus Collaboration, ¹Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁴St. Vincent’s Hospital, Melbourne, Australia, ⁵Medicine/Rheumatology, National University Health System, Singapore, Singapore, ⁶Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ⁷Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁸63 Sutton Street, St. Vincent’s Hospital, Melbourne, Australia, ⁹Melbourne University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) has historically lacked clear treat-to-target definitions. The recently reported Lupus Low Disease Activity State (LLDAS) definition, combining disease activity and…
Abstract Number: 795 • 2016 ACR/ARHP Annual Meeting
Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?
Chiara Tani¹, Roberta Vagelli¹, Chiara Stagnaro², Linda Carli^3,4, Viola Signorini⁵ and Marta Mosca¹, ¹Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ³GenOMec PhD, University of Siena, Italy, ⁴Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁵Rheumatology Unit, Pisa, Italy
Background/Purpose: To date, there is no generally accepted definition for remission in SLE, thus a possible goal in the treat-to-target strategy might be low disease…
Abstract Number: 1051 • 2016 ACR/ARHP Annual Meeting
Determining the Minimal Clinically Important Difference for Improvement for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)
Zahi Touma¹, Dafna D Gladman², Dorcas Beaton³, Jiandong Su⁴ and Murray Urowitz¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50) is a reliable and valid index able to measure ≥ 50% improvement in disease…
Abstract Number: 1787 • 2016 ACR/ARHP Annual Meeting
Increased Heart Rate Variability Reflects Improvement in Clinical Status of Patients with Systemic Lupus Erythematosus
Aikaterini Thanou¹, Stavros Stavrakis², John W. Dyer², Stan Kamp³, Judith A. James⁴ and Joan T. Merrill³, ¹Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Decreased heart rate variability (HRV) is a sign of potentially serious cardiac morbidity and is known to reflect autonomic dysfunction and inflammatory dysregulation (1).…
Abstract Number: 1793 • 2016 ACR/ARHP Annual Meeting
Visceral Adiposity Assessed By DXA in Juvenile-Onset Systemic Lupus Erythematosus: A Correlation with Damage Index and Disease Duration
Juliane Paupitz¹, Glauce Lima¹, Nadia E Aikawa¹, Liliam Takayama¹, Luciana Seguro², Eloisa Bonfa³ and Rosa M R Pereira⁴, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil
Background/Purpose: Young woman with lupus (SLE) are at increased risk of early atherosclerosis leading to cardiovascular disease in adult life and consequently higher morbidity and…
Abstract Number: 1815 • 2016 ACR/ARHP Annual Meeting
Frequency and Predictors of Attaining the Lupus Low Disease Activity State (LLDAS) in a Multinational SLE Cohort from the Asia Pacific
Vera Golder¹, Rangi Kandane-Rathnayake², Alberta Y. Hoi³, Molla Huq⁴, Worawit Louthrenoo⁵, Yuan An⁶, Zhanguo Li⁶, Shue Fen Luo⁷, Sargunan Sockalingam⁸, Chak Sing Lau⁹, Alfred Lee¹⁰, Mo Yin Mok¹⁰, Aisha Lateef¹¹, Kate Franklyn³, Susan Morton¹², Sandra V. Navarra¹³, Leonid Zamora¹³, Yeong-Jian Wu⁷, Laniyati Hamijoyo¹⁴, Madelynn Chan¹⁵, Sean O'Neill¹⁶, Fiona Goldblatt¹⁷, Eric F Morand³, Mandana Nikpour¹⁸ and Asia Pacific Lupus Collaboration, ¹Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Rheumatology, Monash University, Melbourne, Australia, ³Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁴Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ⁵Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁶Peking University People's Hospital, Beijing, China, ⁷Chang Gung University, Taoyuan County, Taiwan, ⁸University of Malaya, Kuala Lumpur, Malaysia, ⁹Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹⁰Queen Mary Hospital, Hong Kong, Hong Kong, ¹¹Medicine/Rheumatology, National University Health System, Singapore, Singapore, ¹²Monash Health, Melbourne, Australia, ¹³Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁴University of Padjadjaran, Bandung, Indonesia, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶University of New South Wales, Sydney, Australia, ¹⁷Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Melbourne University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable burden from disease activity and damage. A novel clinical treatment target in the…
Abstract Number: 765 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway
Chaim Putterman¹, Jill P. Buyon², Richard Furie³, Rosalind Ramsey-Goldman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁷, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²NYU School of Medicine, New York, NY, ³NSLIJHS, Lake Success, NM, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁷Research and Development, Exagen Diagnostics, Vista, CA, ⁸Exagen Diagnostics, Vista, CA
Background/Purpose : There is a need to identify biomarkers that track disease response in systemic lupus erythematosus (SLE). The value of various biomarkers in monitoring…
Abstract Number: 766 • 2015 ACR/ARHP Annual Meeting
Clinical and Immunological Characteristics of 150 Systemic Lupus Erythematosus Patients in Urban Jamaica
Keisha Maloney¹, Trevor Ferguson² and Karel De Ceulaer³, ¹Department of Medicine,, University of the West Indies, Kingston 7, Jamaica, ²Epidemiology Research Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston 7, Jamaica, ³Internal Medicine, University of the West Indies, Kgn 7, Jamaica
Background/Purpose: Epidemiological studies in systemic lupus erythematosus (SLE) have been reported in the literature in many countries and ethnic groups. Although SLE in Jamaica has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].